Tuesday, August 24, 2010

ACTC to Hot to Touch?

Today ACTC announced that their proprietary “embryo-safe” technology will not fall under the recent ban placed on embryonic stem cell research.

Aug. 24, 2010 (Business Wire) -- Advanced Cell Technology, Inc. ("ACT”; OTCBB:ACTC stock news) commented today on yesterday’s federal court ruling, temporarily blocking federal funding for embryonic stem cell research involving the destruction of embryos. The company believes that this will add to the pressure on the NIH to find appropriate sources of human ES cells that can be funded in the context of this preliminary injunction. It is notable, then, that ACT’s proprietary “embryo-safe” Single Blastomere technique for deriving human embryonic stem cells (hESCs), documented in Nature and CELL Stem Cell magazines and elsewhere, does not require destruction of the embryo and as a consequence may not be directly affected by this ruling. ACT does not rely on government funding for any of its research or product development. Accordingly, there is no current impact on the company’s business.

We are not investment advisers, contact one before making any investment decision! Investing in penny stocks can result in total loss of investment.

No comments: